anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Vietnam and Saudi Arabia have some of the highest disease burdens of liver cancer globally. Early detection in asymptomatic patients who are at risk for liver is a strategy to improve survival outcomes in liver cancer management. GALAD score (gender, age, alpha-feto protein (AFP)-L%, AFP and DCP) is a serum biomarker-based panel that can improve HCC early detection in patients with liver fibrosis and cirrhosis. In case-control studies and studies with the design of prospective specimen collection, and retrospective blinded evaluation, GALAD has demonstrated promising clinical utility. However, in order to ascertain its potential role in the surveillance of liver cancer early detection, GALAD needs to be validated prospectively for clinical surveillance of liver cancer (i.e. phase IV biomarker validation study). Thus, the investigators propose to conduct a phase IV biomarker validation study to prospectively survey a cohort of patients at risk for HCC (i.e. patients with compensated cirrhosis and irrespective of cirrhosis etiologies), using semi-annual abdominal ultrasound and GALAD Score for 5 years. In doing so, the investigators aim to validate the potential role of GALAD Score for clinical surveillance and early detection of HCC in Vietnam and Saudi Arabia. Additionally, the investigators will collect and archive biospecimens to develop a bio-repository for liver disease. The biorepository will encourage the sharing of biospecimens and collaboration among physicians or physician-researchers between the US, Vietnam, and Saudi Arabia.
The method for producing the immunobiologic composition in the form of the gel for treating staphylococcal pyodermia comprises forming the gel by mixing gel-forming components in the liquid medium, adding the alkaline neutralizer, and the preserving agent. The antistaphylococcus bacteriophage with lytic activity of at least 10according to Appelman is used as the medium. The method comprises three steps. First, 4/5 of the total amount of the bacteriophage solution is taken and mixed with carbomer followed by the adjustment of pH to 7.3±0.3 with the aid of the alkaline neutralizer. At the second step, to the melted macrogol the preserving agent and the rest of the bacteriophage solution are added successively in constant stirring. Finally, the products of the first and second steps are combined.
INTRODUCTION: Middle cluneal nerve (MCN) entrapment around the sacroiliac joint elicits low back pain (LBP). For surgical decompression to be successful, the course of the MCN must be known. We retrospectively studied the MCN course in 15 patients who had undergone MCN neurolysis.
METHODS: Enrolled in this retrospective study were 15 patients (18 sides). We inspected their surgical records and videos to determine the course of the entrapped MCN. The area between the posterior superior- and the posterior inferior iliac spine was divided into areas A-D from the rostral side. The MCN transit points were identified at the midline and the lateral edge connecting the posterior superior- and posterior inferior iliac spine. Before and 6 months after surgery, the patients recorded the degree of LBP on the numerical rating scale and the Roland-Morris Disability Questionnaire.
RESULTS: We decompressed 24 MCNs. The mean number was 1.3 nerves per patient (range 1-2). The MCN course was oblique in the cranio-caudal direction; the nerve tended to be observed in areas C and D. In six patients (40%), we detected two MCN branches, they were in the same area and adjacent. Postoperatively, LBP was improved significantly in all patients.
CONCLUSION: Between the posterior superior- and the posterior inferior iliac spine, the MCN ran obliquely in the cranio-caudal direction; it was prominent in areas on the caudal side. In six (40%) patients, we decompressed two adjacent MCNs. Our findings are useful for MCN decompression surgery.
Usual care from SingHealth Polyclinics with wireless HBPM system. In addition, participants will receive a medication event monitoring system and will be on ambulatory blood pressure monitoring at baseline and Month 6.
Physical exercise and dieting are well-known and effective methods for fat loss and improving cardiovascular health. However, different individuals often react differently to the same exercise regimen or dietary plan. While specific individuals may undergo substantial fat loss, others may observe only limited effects. A wide range of inter-individual variability in weight gain and changes in body composition induced by physical exercises and diets led to an investigation into the genetic factors that may contribute to the individual variations in such responses. This systematic review aimed at identifying the genetic markers associated with fat loss resulting from diet or exercise. A search of the current literature was performed using the PubMed database. Forty-seven articles met the inclusion criteria when assessing genetic markers associated with weight loss efficiency in response to different types of exercises and diets. Overall, we identified 30 genetic markers of fat-loss efficiency in response to different kinds of diets and 24 in response to exercise. Most studies (n = 46) used the candidate gene approach. We should aspire to the customized selection of exercise and dietary plans for each individual to prevent and treat obesity.
Steroid-refractory chronic graft-versus-host disease (cGvHD) is associated with significant morbidity and mortality, with ruxolitinib being the first drug approved for its treatment. We retrospectively analyzed the safety and efficacy of ruxolitinib for treatment of cGvHD at our center between 07/2015 and 12/2022 and identified 48 patients receiving ruxolitinib as second (18/48) or advanced (30/48) treatment line. Ruxolitinib was started on median day 340 (range 119-595) after cGvHD onset; median duration of administration was 176 (range, 79-294) days with 16/48 patients continuing treatment at last follow-up. National Institutes of Health organ grading and the intensity of immunosuppression were assessed at the start of ruxolitinib treatment and repeated after 1, 3, 6, and 12 months. Response assessment was terminated at the start of any additional new immunosuppressant treatment. The median time of follow-up was 582 (range, 104-1161) days. At the primary analysis after six months on ruxolitinib treatment, the overall response rate was 33%, and failure-free survival was 58%. Infectious adverse events ≥ CTCAE grade III were observed in 10/48 patients. The response rate was not associated with the severity of cGvHD, number of previous treatment lines, or number of additional agents combined with ruxolitinib applying a univariate regression model. At the time of the 12-month follow-up, four patients experienced recurrence of the underlying malignancy and two patients had experienced non-relapse-related mortality. Overall, ruxolitinib was relatively well-tolerated and showed outcomes comparable to the REACH3 trial in a heavily pretreated patient population.
The present disclosure relates to a method for operating a skin damage treatment system, which comprises the following steps. A user terminal receives an image related to the skin damage to a user. The user terminal receives information related to the skin damage from the user. The user terminal transmits the image related to the skin damage and the information related to the skin damage to a service server. The service server determines a risk level based on the image related to the skin damage and the information related to the skin damage. When the risk indicates mild, the service server transmits information related to the treatment method to the user terminal. When the risk is mild, the service server transmits the image related to the skin damage, the information related to the skin damage, and the information related to the treatment method to a medical personnel terminal. When the risk indicates severe, the service server transmits at least one hospital information selected based on a location of the user included in the information related to skin damage to the user terminal.
FIELD: cosmetics, domestic chemistry, hairdressing, fixing of hairdo. SUBSTANCE: tone hair spray has film forming materials, ethyl alcohol, aromatic compounds, propellents or conservatory agents, due stuff and CO 2 -extracts of carrot seeds. Additional ingredients are fed into the hair spray. They are: vitamin concentrate, combined CO 2  extract of cacao husk and laurel or infusion of ginseng biomass and also a mixture of combined CO 2 - extract of carrot seed and rice wastes with CO 2 -extract of parsley seeds. CO 2 -extract of eucalyptus or fennel seeds are also added. Above-mentioned balanced and valid film-forming and bioactive ingredients are introduced to tone hair spray for reacting and combining with resins of dye-stuffs also with ethyl alcohol and conservatory agents with the result that the hair spray can turn pliable and protective and provides for strong fixation and hair vitaminizing. Toning and golden tinge is achieved but the hair when spread are never sticky. EFFECT: high ductility of hair spray, intensified natural blonde color due to using bioactive materials and phytoextracts and infusions. 2 tbl
Cisplatin is an antimitotic drug able to cause acute and chronic gastrointestinal side effects. Acute side effects are attributable to mucositis while chronic ones are due to neuropathy. Cisplatin has also antibiotic properties inducing dysbiosis which enhances the inflammatory response, worsening local damage. Thus, a treatment aimed at protecting the microbiota could prevent or reduce the toxicity of chemotherapy. Furthermore, since a healthy microbiota enhances the effects of some chemotherapeutic drugs, prebiotics could also improve this drug effectiveness. We investigated whether chronic cisplatin administration determined morphological and functional alterations in mouse proximal colon and whether a diet enriched in prebiotics had protective effects. The results showed that cisplatin caused lack of weight gain, increase in kaolin intake, decrease in stool production and mucus secretion. Prebiotics prevented increases in kaolin intake, changes in stool production and mucus secretion, but had no effect on the lack of weight gain. Moreover, cisplatin determined a reduction in amplitude of spontaneous muscular contractions and of Connexin (Cx)43 expression in the interstitial cells of Cajal, changes that were partially prevented by prebiotics. In conclusion, the present study shows that daily administration of prebiotics, likely protecting the microbiota, prevents most of the colonic cisplatin-induced alterations.
Interleukin-33 (IL-33), an emerging cytokine within the IL-1 family, assumes a pivotal function in the control of obesity. However, the specific mechanism of its regulation of obesity formation remains unclear. In this study, we found that the expression level of IL-33 increased in visceral adipose tissue in mice fed with a high-fat diet (HFD) compared with that in mice fed with a normal diet (ND). In vitro, we also found the expression level of IL-33 was upregulated during the adipogenesis of 3T3-L1 cells. Functional test results showed that knockdown of IL-33 in 3T3-L1 cells differentiation could promote the accumulation of lipid droplets, the content of triglyceride and the expression of adipogenic-related genes (i.e. PPAR-γ, C/EBPα, FABP4, LPL, Adipoq and CD36). In contrast, overexpression of IL-33 inhibits adipogenic differentiation. Meanwhile, the above tests were repeated after over-differentiation of 3T3-L1 cells induced by oleic acid, and the results showed that IL-33 played a more significant role in the regulation of adipogenesis. To explore the mechanism, transcriptome sequencing was performed and results showed that IL-33 regulated the PPAR signaling pathway in 3T3-L1 cells. Further, Western blot and confocal microscopy showed that the inhibition of IL-33 could promote PPAR-γ expression by inhibiting the Wnt/β-catenin signal in 3T3-L1 cells. This study demonstrated that IL-33 was an important regulator of preadipocyte differentiation and inhibited adipogenesis by regulating the Wnt/β-catenin/PPAR-γ signaling pathway, which provided a new insight for further research on IL-33 as a new intervention target for metabolic disorders.
The invention discloses ichnocarpus polyanthus decoction pieces and a preparation method thereof. The decoction pieces mainly comprise ichnocarpus polyanthus, malt, eucommia ulmoides, citrus chirocarpus, cockscomb, sweet wormwood and brown sugar. The decoction pieces are prepared from, by weight, 70-80 parts of ichnocarpus polyanthus, 3-7 parts of malt, 0.8-1.2 parts of eucommia ulmoides, 0.8-1.2 parts of citrus chirocarpus, 0.8-1.2 parts of cockscomb, 3-7 parts of sweet wormwood and 3-7 parts of brown sugar. The decoction pieces are prepared by using various primitive plants. Not only the original medicinal properties of the plants are preserved to be intact, but also the side effect is non-existent. The ichnocarpus polyanthus decoction pieces are a highly nutritious health care product with the functions of expelling wind and removing dampness, activating blood and stopping bleeding and the like.
Ten study visits will be completed by each participant. The initial visit will include a blood draw and a baseline memory evaluation. Afterwards, participants will be randomized to begin with one of 3 conditions of HD-tDCS. The three conditions are sham-control, active stimulation to frontal region, and active stimulation to left temporal region. All participants will be expected to completed each HD-tDCS condition, which will be counterbalanced and separated by 14 days. Active HD-tDCS will be applied at 2 mA for 30 minutes over 3 consecutive daily sessions while sham stimulation will be applied for the same duration and timespan. All subjects will complete memory assessments again immediately following each HD-tDCS condition for a total of four test sessions.
FIELD: medicine, pharmacy. SUBSTANCE: medicinal preparation relates to phytopreparations and can be used as basic agent for treatment of monoarthritis, polyarthritis, arthrosis. Preparation has a spirituous tincture at the following ratio of components, mas. p.: elecampane roots 2-5; marsh cinquefoil roots 1-4; birch buds 0.5-1.5, and alcohol - the rest. Composition can contain also spirituous tincture of pantocrin or ginseng. Method involves by turn administration of indicated components at heating, periodic solution shaking. EFFECT: enhanced effectiveness of treatment.
Sepsis-related acute kidney injury (SAKI) is a complication leading to morbidity and mortality in septic patients. Some 50% of AKI patients in the Intensive Care Unit (ICU) are sepsis patients, which is the highest cause of death in the ICU. In sepsis, there is systemic inflammation that causes endothelial damage, which manifests in capillary leakage. Fluid accumulation that has occurred since the patient came to the hospital due to a capillary leak in sepsis and is exacerbated by fluid resuscitation has a negative impact on the kidneys. Therefore, the aim of this study was to assess the effectiveness of early de-resuscitation using furosemide on the incidence of AKI in septic patients using pNGAL as a parameter of AKI.

This study used a double-blind, randomized clinical trial design. This study was conducted on septic patients with a cumulative balance of \>1500 mL/day and urine output of 0.8 cc/kg/hour in the ICU of Dr. Cipto Mangunkusumo National Central Public Hospital in the July-December 2023 period. pNGAL levels were checked at the 0th and 48th hours of ICU care. A total of 48 subjects were divided into 2 groups: 24 patients in the treatment group were given a continuous injection of furosemide at 2 mg/hour, and 24 patients in the control group were given a placebo injection at 2 mg/hour. The patient's condition will be followed after the ICU stay for up to 28 days to record the need for renal replacement therapy and death.
This randomized clinical trial will be conducted at Sir Ganga Ram Hospital in 7 months. 62 participants with Bell's palsy will be included as per sample size calculation through convenience sampling technique. Participants which meet inclusion criteria will be randomly allocated using online randomization tool into two groups. Group A will receive Mime therapy for 30 minutes with short resting interval and Group B will receive action observation therapy for 30 minutes. Each group will receive treatment session of 5 days per week for 6 weeks.

Facial symmetry will be measured using the 13-item Sunny Brook facial Grading System, Facial disability index will be used to assess the quality of life and The House-Brackmann Facial Nerve Grading System will be used to characterize the degree of facial paralysis. The data will be analyzed using SPSS version 24 for Windows software.
Autologous peripheral blood mononuclear cell (PBMC) will be obtained by leukapheresis over one day. Daily intravenous (IV) infusion of fludarabine and cyclophosphamide for total of 3 days (Days -5, -4, -3). The dose of cyclophosphamide will be given at 500mg/m2. The dose of fludarabine will be given at 30mg/m2. CD19-CD34 CAR transduced T cells will be administered IV at a dose level of 1.5 x 106 transduced T cells/kg.
The effects of exercise on fibro-adipogenic progenitors (FAPs) are unclear, and the direct molecular link is still unknown. In this study, we reveal that exercise reduces the frequency of FAPs and attenuates collagen deposition and adipose formation in injured or disused muscles through Musclin. Mechanistically, Musclin inhibits FAP proliferation and promotes apoptosis in FAPs by upregulating FILIP1L. Chromatin immunoprecipitation (ChIP)-qPCR confirms that FoxO3a is the transcription factor of FILIP1L. In addition, the Musclin/FILIP1L pathway facilitates the phagocytosis of apoptotic FAPs by macrophages through downregulating the expression of CD47. Genetic ablation of FILIP1L in FAPs abolishes the effects of exercise or Musclin on FAPs and the benefits on the reduction of fibrosis and fatty infiltration. Overall, exercise forms a microenvironment of myokines in muscle and prevents the abnormal accumulation of FAPs in a Musclin/FILIP1L-dependent manner. The administration of exogenous Musclin exerts a therapeutic effect, demonstrating a potential therapeutic approach for muscle atrophy or acute muscle injury.
AST-201 is a novel aptamer drug conjugate (ApDC) investigational agent with demonstrated preclinical efficacy in GPC3-positive tumor models. This Phase 1 clinical study aims to investigate the safety, tolerability, and preliminary efficacy of AST-201, targeting GPC3-positive advanced solid tumors. The study consists of two parts: Phase 1a and Phase 1b.

In Phase 1a, AST-201 will be administered in a dose escalating manner across cohorts of patients to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). In this dose-escalation phase, patients will receive AST-201 as a single agent, with safety, tolerability, and pharmacokinetic (PK) profiles assessed. In Phase 1b, patients will receive AST-201 at the RP2D across specific GPC3-positive tumor types to further explore safety and efficacy. This expansion phase focuses on assessing anti-tumor efficacy and overall safety in a broader patient population. Data collected from this study will support future clinical development of AST-201 in GPC3-positive advanced solid tumors.
Thumb carpometacarpal or basal joint arthritis is the second most common location for osteoarthritis in the hand. It mainly affects women over 50years of age. Basal joint arthritis causes pain, loss of strength during pinch grips, and eventually stiffness and progressive deformity of the thumb column. Conservative treatment must be implemented first. It aims to spare the joint by using standardized methods. It must be initiated as soon as pain starts, not once the deformity has settled in. There is broad agreement that surgery is indicated when pain relief is not achieved after at least 6months of conservative treatment. The available surgical techniques can be classified as joint-sparing (extra-articular) and joint-sacrificing (intra-articular). The former consists of trapeziometacarpal stabilizing ligament reconstruction, subtraction osteotomy of the first metacarpal and thumb carpometacarpal denervation. The latter consists of trapeziometacarpal fusion, trapeziectomy (and its variants) and implant arthroplasty. Except in very specific cases, trapeziectomy and trapeziometacarpal implant arthroplasty with a total joint prosthesis or an interposition implant are the two main surgical techniques for treating basal joint arthritis. After reviewing the pathophysiology and the diagnosis of thumb basal joint arthritis, we will provide an overview of the available treatment options, with emphasis on the accepted surgical strategies in 2023. LEVEL OF EVIDENCE: III.
The invention relates to a traditional Chinese medicine composition for treating candidiasis. The traditional Chinese medicine composition is characterized by being prepared by the following medicine materials by weight: 8-12g of American ginseng, 6-9g of rhizoma polygonati roots, 6-8g of the fruit of Chinese wolfberry, 6-10g of radix asparagi, 6-9g of golden cypress, 8-12g of jasmine, 6-9g of Chinese violet, 6-8g of akebiaquinata, 6-10g of semen coicis, 6-9g of radix achyranthis bidentatae, 4-6g of zaocys dhumnade, 6-10g of radix sophorae flavescentis, 4-6g of oldenlandia diffusa and 6-9g of poria cocos. A medicine for external use is prepared by 20g of radix sophorae flavescentis, 20g of cotex dictamni, 20g of garter snake, 10g of Chinese violet and 5g of borneol, wherein the raw materials are decocted for partial hydropathic compress. The traditional Chinese medicine composition for treating candidiasis has the advantages of strengthening body resistance and eliminating evil, eliminating dampness and heat and killing worm and relieving itching. The treatment depends on different symptoms clinically. The traditional Chinese medicine composition for treating candidiasis is low in side effect, fast in curative effect, high in cure rate and free of side and toxic effect.
PCT No. PCT/EP97/00507 Sec. 371 Date Apr. 8, 1998 Sec. 102(e) Date Apr. 8, 1998 PCT Filed Jan. 31, 1997 PCT Pub. No. WO97/27841 PCT Pub. Date Aug. 7, 1997A dual chambered dispensing system allows for application of an aqueous composition containing a biologically effective compound which is adequately stabilized. The system separately contains the stabilized biologically effective compound composition in one chamber and an aqueous basic composition in the other. Both compositions are simultaneously delivered from the dispensing system, whereupon the compositions are mixed to result in a final composition suitable for direct application.
Nanoparticles are used increasingly in consumer products and biomedical applications. Yet the cellular interaction mechanism at the molecular level is not well understood for nanomaterials of different size, shape and surface chemistry. Gold nanoparticles (Au-NPs), which have been explored extensively for various applications in recent years, are used as the model system to help understand the size-dependent biological effects of nanoparticles. Jurkat cells treated with Au-NPs ranging from 2 nm to 200 nm were studied. Whole genome expression measurements indicate size-dependent effects, including linear scaling and threshold effects. In addition, a non-linear pattern of gene responses that persisted over time were observed in 20-40 nm Au-NP treated cells. Gene function, promoter, and pathway analyses reveal differential signaling processes that are correlated with nanoparticle sizes. The size may play a role in cellular sorting of naturally occurring particulates, particle interaction with the receptors, intracellular transportation, signaling and stress responses.